| 7 0.15 (2.19%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.01 |
1-year : | 10.53 |
| Resists | First : | 7.71 |
Second : | 9.01 |
| Pivot price | 6.99  |
|||
| Supports | First : | 6.7 |
Second : | 6.07 |
| MAs | MA(5) : | 6.83 |
MA(20) : | 7.03 |
| MA(100) : | 5.41 |
MA(250) : | 4.54 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 23.5 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 7.71 | Low : | 2.99 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PGEN ] has closed below upper band by 49.4%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.02 - 7.07 | 7.07 - 7.1 |
| Low: | 6.67 - 6.72 | 6.72 - 6.76 |
| Close: | 6.93 - 7.01 | 7.01 - 7.08 |
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Mon, 14 Sep 2026
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? - Yahoo Finance
Fri, 28 Aug 2026
Precigen (PGEN) Draws Attention To Papzimeos, Is The Valuation Upside Already Priced In? - Yahoo Finance
Fri, 28 Aug 2026
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Wed, 26 Aug 2026
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Sat, 08 Aug 2026
Precigen: Has To Grow Into Its Valuation - Seeking Alpha
Tue, 04 Aug 2026
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 358 (M) |
| Held by Insiders | 1.9465e+008 (%) |
| Held by Institutions | 12.6 (%) |
| Shares Short | 41,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.536e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -184 % |
| Operating Margin | 41.1 % |
| Return on Assets (ttm) | -18.2 % |
| Return on Equity (ttm) | -837.1 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 316.37 |
| Sales Per Share | 8.40392e+007 |
| EBITDA (p.s.) | 4.4549e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 59.5 |
| Dividend | 0 |
| Forward Dividend | 4.224e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|